This session will provide patients, caregivers, and healthcare professionals with a comprehensive understanding of MASLD and its impact on patients' lives. The session will feature patient testimonials, expert presentations, and interactive discussions ai

This session is designed to provide patients, caregivers, and healthcare professionals with a comprehensive understanding of liver cancer and its impact on patients' lives. The session will feature patient testimonials, expert presentations, and interacti

Is Palliative Care and Hospice the same thing?  As a chronic liver disease or end-stage liver patient how can focusing on frailty and palliative care actually improve patient outcomes? Palliative Care provides excellent resources for patients and their ca

Every provider and patient communicate differently. During this program we will discuss ways to relay patient wants/needs to the provider; while also making sure the provider is able to educate the patient/caregiver. We will be sharing examples of pre-app

In this session learners will gain a better understanding of the role of innate immunity and innate immune cells in the regulation of hepatic fibrosis. The paracrine role of innate immune cells with fibrogenic cells and potential therapeutic interventions

The American Academy of Pediatrics recommends early and proactive treatment for children who have obesity, including surgery or weight loss drugs. However, the application of these recommendations to Pediatric MASLD are not clear.

The new definition of HRS_AKI has broadened the field and it has many implications including resource utilization in an in-patient setting. A critical appraisal of the definition and cost assessment will be meaningful.

Alcohol-associated liver disease has increased over the last year. It is needed to understand the changes in trends, factors affecting this, and potential interventions.

ALD is one of the most common causes of liver disease. Early identification is key. This MTEs session will discuss screening strategies and how to identify ALD at a population level